Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.77 |
| ▸ | MTOR | P42345 | 5/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.77 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.77 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.77 |
| ▸ | PRKDC | P78527 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.77 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.77 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.77 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.77 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.77 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.77 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624445 | 0.88 | PIK3CA (0.73) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL15599518 | 0.87 | PIK3CA (0.74) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL29352875 | 0.87 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL623194 | 0.87 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL29358168 | 0.87 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL25495122 | 0.81 | PIK3CA (0.83) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL20734873 | 0.80 | PIK3CA (0.88) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17060461 | 0.79 | PIK3CA (0.78) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL731865 | 0.79 | PIK3CA (0.72) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL25494702 | 0.78 | PIK3CA (0.66) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603078-A1 | COMBINATION | GlaxoSmithKline LLC (US) | 2013-06-19 | — | — | EP | claimed |
| US-20130137701-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2013-05-30 | — | — | US | claimed |
| WO-2012021480-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-02-16 | — | — | WO | claimed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-9974774-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-08-04 | — | — | US | disclosed |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | PIK3CA 426/4885MTOR 2949/4885PIK3CD 1353/4885 |
| US-20130137701-A1 | COMBINATION | KRAS, NQO2, QDPR | PIK3CA 1234/4885MTOR 3366/4885PIK3CD 2659/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | PIK3CA 426/4885MTOR 2949/4885PIK3CD 1353/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | PIK3CA 1050/4885MTOR 2890/4885PIK3CD 2262/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885MTOR 2086/4885PIK3CD 2515/4885 |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | PIK3CA 1050/4885MTOR 2890/4885PIK3CD 2262/4885 |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885MTOR 2086/4885PIK3CD 2515/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | PIK3CA 1050/4885MTOR 2890/4885PIK3CD 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.